

### Lopinavir/ritonavir

S

#### Acute liver failure following compassionate use: case report

In a retrospective cohort study involving 42 patients with COVID-19 infection admitted to an ICU in France between 27 February 2020 and 21 March 2020, a patient [*age and sex not stated*] was described who developed acute liver failure during compassionate use of lopinavir/ritonavir for COVID-19 infection.

The patient with COVID-19 infection, started receiving compassionate treatment with lopinavir/ritonavir 400/100mg every 12h, scheduled for 14 days [*route not stated*]. However, the patient developed jaundice and was diagnosed with treatment-related acute liver failure requiring extraorporeal membrane oxygenation [*duration of treatment to reaction onset not stated*]. The patient did not recover from jaundice and eventually died of multiorgan failure. The patient's death was reported to be unrelated to acute liver failure.

Levy C, et al. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice. *American Journal of Gastroenterology* 115: 1716-1718, No. 10, Oct 2020. Available from: URL: <http://doi.org/10.14309/ajg.0000000000000828>

803514772